

**Mapping Dysfunctional Circuits in the Frontal Cortex**  
**Using Deep Brain Stimulation (Hollunder et al.):**  
***Supplementary Tables***

**Table of Contents**

<b>Supplementary Tables</b>	<b>p. 2</b>
<b>Table S1:</b> Summary of demographic and clinical patient characteristics within each discovery cohort.	<b>p. 2</b>
<b>Table S2:</b> Patient-wise demographic and clinical characteristics of the dystonia discovery cohorts.	<b>p. 4</b>
<b>Table S3:</b> Patient-wise demographic and clinical characteristics of the Tourette's syndrome discovery cohorts.	<b>p. 7</b>
<b>Table S4:</b> Patient-wise demographic and clinical characteristics of the Parkinson's disease discovery cohorts.	<b>p. 8</b>
<b>Table S5:</b> Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder discovery cohorts.	<b>p. 12</b>
<b>Table S6:</b> Summary of demographic and clinical patient characteristics within each retrospective model validation cohort.	<b>p. 13</b>
<b>Table S7:</b> Patient-wise demographic and clinical characteristics of the Parkinson's disease validation cohorts.	<b>p. 15</b>
<b>Table S8:</b> Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder validation cohorts.	<b>p. 17</b>
<b>Table S9:</b> Peak voxel coordinates of subthalamic sweet spots and of disease-specific cortical sites of interconnection with sweet tracts.	<b>p. 19</b>
<b>Table S10:</b> Overlap between connected streamlines shared among disorders and disease-specific sweet streamlines.	<b>p. 20</b>
<b>Table S11:</b> Patient-wise demographic and clinical characteristics of patient cases for prospective model validations.	<b>p. 20</b>
<b>References</b>	<b>p. 22</b>

**Table S1:** Summary of demographic and clinical patient characteristics within each discovery cohort.

Disease cohort	DYT		PD		TS		OCD	
<b>Demographic Information</b>								
<b>Cohort</b>	San Francisco	Shanghai	Berlin	Würzburg	Pisa/Milan	Shanghai	London	Grenoble
<b>Surgical DBS center</b>	University of California San Francisco	Ruijin Hospital Shanghai	Charité - Universitäts-medizin Berlin	University Hospital Würzburg	Fondazione IRCCS Instituto Neurologico Carlo Besta Milan	Ruijin Hospital Shanghai	National Hospital for Neurology and Neurosurgery	University Hospital Grenoble
<b>N (female)</b>	12 (7)	Main*: 44 (23); Full: 58 (31)	51 (17)	43 (12)	4 (2)	10 (1)	6 (1)	13 (9)
<b>Age at time of surgery (mean ± SD; range; in years)</b>	56.08 ± 16.06; 16-68	Main*: 39.43 ± 21.06, 7-74; Full: 41.90 ± 20.60, 7-74	59.98 ± 7.93.; 42-75	60.49 ± 8.23; 46-74	34.00 ± 8.83; 26-46	23.10 ± 9.39; 14-38	45.50 ± 10.52; 37-62	39.15 ± 8.23; 27-53
<b>Disease duration at time of surgery (mean ± SD; range; in years)</b>	9.50 ± 9.54; 2-32	Main*: 5.94 ± 7.01, 0.5-30; Full: 5.15 ± 6.36, 0.25-30	10.38 ± 3.85; 5-21	12.53 ± 4.46; 5-23	24.25 ± 6.08; 19-33	14.8 ± 9.38; 3-30	24.17 ± 3.92; 20-30	18.92 ± 8.96; 5-39
<b>Clinical Outcome</b>								
<b>Main clinical outcome assessment</b>	BFMDRS <sup>1</sup> (total score; range 0-120, with higher scores corresponding to higher symptom burden)		UPDRS-III <sup>2</sup> (total score; range 0-199, with higher scores corresponding to higher symptom burden)		YGTSS <sup>3</sup> (global severity score; range 0-100, with higher scores corresponding to higher symptom burden)		Y-BOCS <sup>4</sup> (total score; range 0-40, with higher scores corresponding to higher symptom burden)	
<b>Time of FU (in months)</b>	6	Main*: mean = 19.09 ± 15.60 SD, range 6-84; Full: mean = 18.00 ± 15.56 SD, range 2-84	12	12	6	6	3 or 6 (post-amSTN phase)*	12
<b>Comparison basis for calculation of improvement values (baseline to DBS stimulation ON conditions)</b>	Pre- to postoperative	Pre- to postoperative	Postoperative ON vs. OFF stimulation (ON dopaminergic medication)	Postoperative ON vs. OFF stimulation (ON dopaminergic medication)	Pre- to postoperative	Pre- to postoperative	Pre- to postoperative	Pre- to postoperative

<b>Score at baseline (mean <math>\pm</math> SD)</b>	16.88 $\pm$ 9.30	Main*: 19.09 $\pm$ 17.68; Full: 16.40 $\pm$ 16.57	38.56 $\pm$ 12.92	49.84 $\pm$ 12.36	89.25 $\pm$ 5.25	69.70 $\pm$ 10.19	36.17 $\pm$ 1.83	33.54 $\pm$ 3.76
<b>Score at time of FU under stimulation ON condition (mean <math>\pm</math> SD)</b>	6.88 $\pm$ 5.90	Main*: 6.02 $\pm$ 9.21; Full: 5.42 $\pm$ 8.33	20.12 $\pm$ 8.82	24.47 $\pm$ 10.62	34.25 $\pm$ 15.97	26.20 $\pm$ 17.92	19.83 $\pm$ 10.57	18.92 $\pm$ 10.74
<b>Rel. improvement (mean <math>\pm</math> SD; in %)</b>	52.07 $\pm$ 41.71	Main*: 69.90 $\pm$ 23.46; Full: 65.24 $\pm$ 28.81	45.34 $\pm$ 23.03	49.46 $\pm$ 23.97	61.50 $\pm$ 17.81	62.31 $\pm$ 26.21	45.00 $\pm$ 29.33	43.59 $\pm$ 31.56
<b>Abs. improvement (mean <math>\pm</math> SD)</b>	10.00 $\pm$ 10.83	Main*: 13.07 $\pm$ 14.72; Full: 10.97 $\pm$ 13.72	18.44 $\pm$ 11.31	25.37 $\pm$ 13.30	55.00 $\pm$ 17.00	43.50 $\pm$ 18.61	16.33 $\pm$ 10.67	14.62 $\pm$ 10.75

Imaging and DBS Specifications								
Imaging modality (postoperatively)	MRI (N = 12)	Main*: CT (N = 44); Full: CT (N = 58)	MRI (N = 45), CT (N = 6)	CT (N = 43)	CT (N = 4)	CT (N = 10)	MRI (N = 6)	MRI (N = 10), CT (N = 3)
Electrode models	MDT 3389 (N = 12)	Main*: MDT 3387 (N = 17), PINS L302 (N = 17), SR 1210 (N = 10); Full: MDT 3387 (N = 22), PINS L302 (N = 26), SR 1210 (N = 10)	MDT 3389 (N = 51)	MDT 3389 (N = 44)	MDT 3389 (N = 4)	MDT 3387 (N = 2), SR 1210 (N = 7), PINS L302 (N = 1)	MDT 3389 (N = 6)	MDT 3389 (N = 14)
Related citation	Ostrem et al., 2011 <sup>5</sup> ; 2016 <sup>6</sup>	Lin et al., 2019 <sup>7</sup> ; He, 2021 <sup>8</sup>	Horn et al., 2017 <sup>9</sup> ; 2019 <sup>10</sup>	Horn et al., 2017 <sup>9</sup> ; 2019 <sup>10</sup>	Vissani et al., 2019 <sup>11</sup>	Dai et al., 2022 <sup>12</sup>	Tyagi et al., 2019 <sup>13</sup>	Polosan et al. 2019 <sup>14</sup>

Notes: \*The full sample of dystonia (DYT) patients from the Shanghai center (N = 58) is based on more liberal inclusion criteria compared to the sample reported on within the main manuscript (N = 44). More conservative exclusion criteria (baseline scores on the Burke-Fahn-Marsden Dystonia Rating Scale [BFMDRS]  $\geq$  5 and times of follow-up for postoperative assessments  $\geq$  6 months) were chosen for main analyses to ensure sufficiently stabilized and comparable deep brain stimulation (DBS) effects across cohorts. Results based on the full sample are reported in the supplements. <sup>a</sup>OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure amSTN” for the first three months or from months four to six postoperatively (and “pure VC/VS” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. AmSTN stimulation was applied via a Medtronic (MDT) model of type 3389, while MDT 3387 leads were implanted for stimulation of the VC/VS target zone (considered only for model validations, see below). Abbreviations: CT, computed tomography; DBS, deep brain stimulation; FU, follow-up; MRI, magnetic resonance imaging; OCD, obsessive-compulsive disorder; PD, Parkinson’s disease; SD, standard deviation; SR, SceneRay; TS, Tourette’s syndrome; UPDRS-III, Unified Parkinson’s Disease Rating Scale – Part III; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale; YGTSS, Yale Global Tic Severity Scale.

**Table S2:** Patient-wise demographic and clinical characteristics of the dystonia discovery cohorts.

SAN FRANCISCO (N = 12)										
Patient Nr.	Age at Surgery (within range, in years)	S e	Disease Duration at Surgery (years)	BFMDRS Baseline (total)	BFMDRS at FU (total)	BFMDRS Percent Improvement at FU (%)	Time of FU (months)	Symptom Sites	Genetic Mutation	Postop. Imaging Modality
1	41-45	F	8	19	2	89	6	oromandibular, cervical	none	MRI
2	46-50	M	7	14	14	0	6	cervical	none	MRI
3	41-45	F	2	34	1	97	6	cervical, trunk	none	MRI
4	36-40	F	9	8	3	63	6	cervical	none	MRI
5	51-55	F	3	12	3	75	6	face, neck	none	MRI
6	46-50	F	4	7	4	43	6	neck	none	MRI
7	51-55	F	32	10	4	60	6	arms	DYT-1 mutation	MRI
8	16-20	M	6	11,5	3,5	70	6	arms, neck	DYT-1 mutation	MRI
9	66-70	M	3	22	12,5	43	6	cervical	none	MRI
10	66-70	F	10	17	5,5	68	6	mouth, neck, and left hand	none	MRI
11	16-20	M	4	35	10	71	6	right arm, neck	DYT-1 mutation	MRI
12	51-55	M	26	13	20	-54	6	neck, arms	none	MRI

  

SHANGHAI (N = 44 in the main analysis, N = 58 in the supplemental analysis)										
Patient Nr.	Age at Surgery (within range, in years)	S e	Disease Duration at Surgery (years)	BFMDRS Baseline (total)	BFMDRS at Follow-Up (total)	Percent Improvement at Follow-Up (%)	FU Period (months)	Dystonia Classification	Genetic Mutation	Postop. Imaging Modality
1	61-65	F	3	18	4,5	75	12	segmental	none	CT
2	41-45	F	1,5	8	5,5	31	15	segmental	none	CT
3	26-30	F	2	10	1	90	11	multi-focal	none	CT
4	21-25	F	5,3	9	2	78	12	generalized	none	CT
5	56-60	M	1,5	9	1,5	83	12	segmental	none	CT
6	56-60	F	1,5	10	2	80	18	segmental	none	CT

7	61-65	F	1,5	19	7	63	18	multi-focal	none	CT
8	71-75	M	1	11	5	55	12	segmental	none	CT
9	66-70	M	10	6	0,5	92	12	focal	none	CT
10	6-10	M	2	26	6	77	9	generalized	DYT-1 mutation	CT
11	31-35	F	2	6	3	50	12	focal	none	CT
12	51-55	M	30	26	7	73	17	multi-focal	DYT-24 mutation	CT
13	6-10	M	2	34	36	-6	12	multi-focal	none	CT
14	51-55	M	1,2	8	2	75	84	focal	none	CT
15	36-40	F	1	16,5	5	70	10	segmental	none	CT
16	36-40	M	6	47,5	1	98	8	generalized	none	CT
17	66-70	M	10	19,5	11	44	11	segmental	none	CT
18	6-10	M	6	24	4	83	24	multi-focal	none	CT
19	16-20	M	1,5	16	1,5	91	12	generalized	none	CT
20	21-25	M	1	5	1,5	70	10	segmental	none	CT
21	66-70	F	8	8,5	4,5	47	48	segmental	none	CT
22	66-70	F	1	11	3	73	30	segmental	none	CT
23	26-30	M	3,5	19	5	74	6	generalized	none	CT
24	41-45	M	3	10,5	4	62	24	generalized	none	CT
25	46-50	F	8	10	0,5	95	24	segmental	none	CT
26	41-45	F	15	8	2	75	30	generalized	none	CT
27	21-25	F	12	30	1	97	15	multi-focal	none	CT
28	11-15	M	2	21	2	90	18	generalized	none	CT
29	31-35	M	28	24	3	88	72	generalized	none	CT
30	51-55	F	6	16,5	4	76	7	generalized	none	CT
31	56-60	F	1,5	6	3	50	30	focal	none	CT
32	66-70	F	9	5	2,5	50	11	segmental	none	CT
33	51-55	F	9	49	49	0	12	multi-focal	none	CT
34	21-25	F	21	20	13	35	24	segmental	none	CT
35	16-20	M	2	92	19,5	79	24	generalized	none	CT
36	71-75	M	6,5	32,5	17	48	12	segmental	none	CT

37	36-40	M	1,5	20	7,5	63	18	generalized	none	CT
38	6-10	M	1	74	11	85	10	generalized	none	CT
39	6-10	F	0,5	16	1	94	13	multi-focal	none	CT
40	16-20	M	1	9	1	89	12	multi-focal	none	CT
41	36-40	F	15	6	1	83	8	segmental	none	CT
42	11-15	F	2	8	1	88	9	segmental	none	CT
43	56-60	F	1	6,5	1,5	77	16	segmental	none	CT
44	21-25	F	14	9	1	89	36	multi-focal	none	CT

*Patients in the following list are included only in the supplemental analysis.*

45	66-70	F	2,5	3	1,5	50	12	segmental	none	CT
46	31-35	M	1,5	4	1	75	24	segmental	none	CT
47	11-15	M	1	26	14,5	44	3	segmental	none	CT
48	51-55	F	0,3	3,5	1,5	57	12	segmental	none	CT
49	51-55	F	1	6	2	67	2	focal	none	CT
50	66-70	F	8,5	3,5	3	14	7	segmental	none	CT
51	46-50	M	3,5	3,5	1	71	60	segmental	none	CT
52	31-35	M	3	28	3	89	4	generalized	none	CT
53	61-65	M	7	8	0,5	94	3	segmental	none	CT
54	61-65	F	4	4	1	75	12	segmental	none	CT
55	46-50	M	0,25	9	12	-33	2	segmental	none	CT
56	71-75	F	3	4,5	5	-11	24	focal	none	CT
57	26-30	F	0,5	4	3	25	24	generalized	none	CT
58	51-55	F	1	4	0,5	88	13	multi-focal	none	CT

*Abbreviations:* BFMDRS, Burke-Fahn-Marsden Dystonia Rating Scale; CT, computed tomography; F, female; FU, follow-up; M, male; MRI, magnetic resonance imaging; Nr., number; postop. postoperative.

**Table S3:** Patient-wise demographic and clinical characteristics of the Tourette's syndrome discovery cohorts.

PISA/MILAN (N = 4)										
Patient Nr.	Age at surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	YGTSS Baseline	YGTSS at 6 mo. After Surgery	Percent Reduction from Baseline at 6 mo. (%)	Type of Tics	Comorbidities	Postop. Imaging Modality	
1	26-30	F	23	92	22	76	pure motor	no OCD or major depression	CT	
2	26-30	M	19	89	20	78	pure motor	no OCD or major depression	CT	
3	31-35	F	22	94	53	44	pure motor	no OCD or major depression	CT	
4	46-50	M	33	82	42	49	pure motor	no OCD or major depression	CT	
SHANGHAI (N = 10)										
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	YGTSS Baseline	YGTSS at 6 mo. After Surgery	Percent Reduction from Baseline at 6 mo. (%)	Motor Tics: Body Regions Involved		Postop. Imaging Modality	
1	16-20	M	11	75	24	68	neck, shoulders, legs, feet		none	CT
2	11-15	M	9	71	4	94	eyes, neck		none	CT
3	11-15	M	3	68	6	91	arms, trunk, legs		none	CT
4	36-40	M	30	71	61	14	nose, mouth, neck, arms, hands, legs		anxiety	CT
5	16-20	F	12	59	8	86	eyes, nose, mouth, neck, shoulders, arms, hands		OCD, depression	CT
6	36-40	M	27	69	33	52	eyes, mouth, neck, shoulders, arms, hands		none	CT
7	16-20	M	6	76	36	53	eyes, mouth, neck, hands, legs		none	CT
8	26-30	M	16	63	17	73	eyes, nose, shoulders, trunk		OCD	CT
9	26-30	M	25	91	35	62	neck, shoulders, arms, legs, feet		OCD	CT
10	11-15	M	9	54	38	30	eyes, mouth, neck		none	CT

Abbreviations: CT, computed tomography; F, female; M, male; mo., months; Nr., number; OCD, obsessive-compulsive disorder; postop., postoperative; YGTSS, Yale Global Tic Severity Scale.

**Table S4:** Patient-wise demographic and clinical characteristics of the Parkinson's disease discovery cohorts.

Pat. Nr.	Age at surgery (within range, in years)		Disease Duration at Surgery (years)		UPDRS-III PD Total Preop.		UPDRS-III Baseline (OFF medication)		UPDRS-III Total Postop. (STIM OFF at 12 Mo.)		UPDRS-III Total Postop. (STIM ON at 12 mo.)		Total Percent Improvement ON vs OFF STIM at 12 mo. postop. (%)		LEDD Baseline (OFF DBS) LEDD at 12 mo. Postop. (ON DBS)		Percent Improvement Levodopa Response	Postop. Imaging Modality
	Sex	Phenotype*	PD pe*	Total Preop.	Baseline (ON Medication)	Total Postop. (STIM OFF at 12 Mo.)	Total Postop. (STIM ON at 12 mo.)	Improvement ON vs OFF STIM at 12 mo. postop. (%)	LEDD Baseline (OFF DBS)	LEDD at 12 mo. Postop. (ON DBS)	LEDD Reduction (%)							
<b>BERLIN (N = 51)</b>																		
1	71-75	F	8	1	20	10	29	30	-3	968	498	49	50	50	MRI			
2	56-60	M	10	1	33	20	41	23	44	900	725	19	39	39	MRI			
3	66-70	F	12	1	n/a	n/a	54	36	33	1000	400	60	31	31	MRI			
4	61-65	M	11	1	33	11	45	30	33	855	640	25	67	67	MRI			
5	66-70	M	6	1	31	18	37	19	49	1035	1115	-8	42	42	MRI			
6	46-50	M	5	1	29	3	39	15	62	610	0	100	90	90	MRI			
7	56-60	F	7	1	n/a	n/a	52	29	44	1150	100	91	72	72	MRI			
8	71-75	F	18	1	n/a	n/a	13	11	15	1500	650	57	26	26	CT			
9	66-70	M	12	1	n/a	n/a	40	20	50	1650	475	71	54	54	CT			
10	61-65	M	11	1	n/a	n/a	44	26	41	900	600	33	46	46	MRI			
11	66-70	M	9	1	27	9	36	22	39	1275	1305	-2	67	67	MRI			
12	51-55	M	7	1	36	20	46	30	35	1620	1000	38	44	44	MRI			
13	66-70	M	14	1	25	14	28	17	39	1640	1398	15	44	44	CT			
14	66-70	F	n/a	1	n/a	n/a	27	29	-7	n/a	n/a	n/a	n/a	n/a	MRI			
15	61-65	M	11	1	16	9	28	13	54	3065	400	87	44	44	MRI			
16	66-70	M	10	1	32	17	29	19	34	1170	780	33	47	47	MRI			
17	51-55	M	8	1	n/a	n/a	24	9	63	1000	267	73	85	85	MRI			
18	56-60	M	7	1	n/a	n/a	32,5	8	75	600	50	92	79	79	CT			
19	71-75	M	9	1	n/a	n/a	27	20	26	1300	700	46	43	43	MRI			
20	71-75	F	5	1	n/a	n/a	24	25	-4	650	700	-8	44	44	MRI			
21	51-55	M	16	1	36	16	33	6	82	700	375	46	56	56	MRI			

22	51-55	M	9	1	42	13	47	10	79	2000	553	72	69	MRI
23	61-65	M	14	1	n/a	n/a	28	15	46	1450	900	38	76	MRI
24	61-65	F	7	1	n/a	n/a	53	19	64	2050	600	71	30	MRI
25	61-65	F	8	1	n/a	n/a	46	28	39	700	200	71	71	MRI
26	61-65	M	7	1	21	12	28	13	54	1125	890	21	43	MRI
27	51-55	M	14	1	n/a	n/a	53	23	57	600	0	100	44	MRI
28	56-60	F	16	1	n/a	n/a	26	13	50	900	300	67	65	MRI
29	51-55	M	16	2	48	18	53	17	68	2438	423	83	63	MRI
30	56-60	M	13	1	n/a	n/a	59	14	76	1150	75	93	50	MRI
31	51-55	F	6	1	43	10	42	35	17	930	n/a	n/a	77	MRI
32	56-60	M	9	1	n/a	n/a	65	21	68	950	700	26	50	MRI
33	56-60	M	10	1	n/a	n/a	24	19	21	800	800	0	n/a	MRI
34	56-60	F	10	1	n/a	n/a	42	13	69	700	200	71	64	MRI
35	66-70	M	21	1	29	8	57	36	37	850	300	65	72	MRI
36	41-45	M	5	1	n/a	n/a	47	17	64	500	0	100	62	MRI
37	46-50	F	12	1	n/a	n/a	36	14	61	683	150	78	n/a	MRI
38	46-50	F	8	1	n/a	n/a	29	18	38	1400	0	100	52	MRI
39	56-60	M	7	1	n/a	n/a	21	9	57	333	50	85	n/a	CT
40	51-55	M	14	2	42	n/a	44	11	75	875	200	77	n/a	MRI
41	66-70	M	15	1	28	11	25	7	72	1328	360	73	61	CT
42	61-65	M	10	1	34	14	33	11	67	1100	720	35	59	MRI
43	66-70	M	17	2	60	21	71	40	44	1453	n/a	n/a	65	MRI
44	51-55	F	9	1	n/a	n/a	67	39	42	1200	375	69	n/a	MRI
45	41-45	F	12	2	n/a	n/a	40	27	33	1025	500	51	53	MRI
46	61-65	M	16	1	n/a	n/a	39	30	23	500	650	-30	31	CT
47	51-55	M	11	1	n/a	n/a	32	10	69	400	0	100	32	MRI
48	61-65	F	10	1	37	12	35	26	26	945	688	27	68	MRI
49	71-75	M	6	2	18	16	33	21	36	400	800	-100	11	MRI
50	51-55	F	5	1	n/a	n/a	45	13	71	750	50	93	25	MRI

51	51-55	M	6	3	13	7	18	20	-11	515	600	-17	46	MRI
<b>WÜRZBURG (N = 43)</b>														
1	51-55	M	13	1	78	46	78	36	54	1280	380	70	41	CT
2	56-60	M	13	1	53	25	53	28	47	1700	0	100	53	CT
3	56-60	M	20	1	43	12	43	15	65	2400	300	88	72	CT
4	66-70	M	16	1	49	18	49	30	39	1333	300	77	63	CT
5	46-50	F	21	1	36	3	36	33	8	1650	200	88	92	CT
6	56-60	F	15	1	43	13	43	25	42	1000	450	55	70	CT
7	61-65	M	15	1	43	8	43	23	47	1400	700	50	81	CT
8	66-70	M	16	1	55	21	55	40	27	2000	1050	48	62	CT
9	51-55	M	6	1	56	30	56	38	32	1275	850	33	46	CT
10	61-65	F	9	1	56	15	56	40	29	1800	700	61	73	CT
11	46-50	F	10	1	73	39	73	22	70	290	0	100	47	CT
12	66-70	M	13	1	71	36	71	40	44	1600	800	50	49	CT
13	66-70	F	12	1	47	14	47	14	70	1100	200	82	70	CT
14	61-65	F	12	1	31	10	31	36	-16	1450	950	34	68	CT
15	56-60	F	15	1	50	15	50	26	48	650	350	46	70	CT
16	71-75	F	17	1	59	15	59	14	76	1400	500	64	75	CT
17	46-50	M	23	1	52	29	52	12	77	1100	100	91	44	CT
18	56-60	M	6	1	43	10	43	13	70	2350	950	60	77	CT
19	66-70	F	14	1	60	19	60	17	72	500	300	40	68	CT
20	61-65	M	9	1	87	18	67	27	60	2000	950	53	79	CT
21	61-65	M	10	1	29	14	29	32	-10	1350	900	33	52	CT
22	51-55	F	6	1	47	18	47	20	57	2850	250	91	62	CT
23	56-60	M	18	1	40	10	40	31	23	1700	900	47	75	CT
24	66-70	M	14	1	51	38	51	23	55	1100	450	59	25	CT
25	51-55	M	5	1	26	3	26	5	81	650	400	38	88	CT
26	46-50	M	11	1	46	11	46	17	63	1100	200	82	76	CT

27	56-60	M	11	1	43	24	43	22	49	1000	150	85	44	CT
28	51-55	M	19	1	50	11	50	15	70	1800	600	67	78	CT
29	51-55	M	10	1	69	14	69	25	64	2600	550	79	80	CT
30	51-55	F	11	1	55	4	55	14	75	1320	980	26	93	CT
31	71-75	M	18	1	57	16	57	29	49	2020	688	66	72	CT
32	46-50	M	21	1	64	41	64	48	25	2320	813	65	36	CT
33	71-75	M	13	1	44	16	44	45	-2	1680	1640	2	64	CT
34	66-70	F	6	1	64	31	64	23	64	1033	460	55	52	CT
35	71-75	M	9	1	38	35	38	7	82	270	0	100	8	CT
36	61-65	M	11	3	38	22	38	19	50	988	105	89	42	CT
37	66-70	M	11	1	40	18	40	24	40	2040	1880	8	55	CT
38	46-50	M	13	1	44	23	44	24	45	1300	800	38	48	CT
39	46-50	M	9	1	37	22	37	22	41	1000	413	59	41	CT
40	61-65	M	10	1	67	18	67	39	42	2395	832	65	73	CT
41	61-65	M	9	1	52	23	52	19	63	916	733	20	56	CT
42	66-70	M	7	1	46	26	46	7	85	1020	443	57	43	CT
43	66-70	M	12	1	31	2	31	13	58	1068	0	100	94	CT

Notes: \*Classification into Parkinson's disease (PD) phenotypes according to Schiess et al (2000)<sup>15</sup>: 1= axial-rigid type. 2 = Mixed type, 3 = tremor dominant type. Abbreviations: CT, computed tomography; F, female LEDD, levodopa equivalent daily dosage; M, male; Mo., months; MRI, magnetic resonance imaging; Nr., number; postop., postoperative; preop., preoperative; STIM, stimulation; UPDRS-III, Unified Parkinson's Disease Rating Scale – Part III.

**Table S5:** Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder discovery cohorts.

**GRENOBLE (N = 13)**

Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS at 12 Mo. after Surgery	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	31-35	M	13	32	26	19	checking, repeating	none	MRI
2	36-40	M	17	32	28	13	washing, ordering	anankastic personality	MRI
3	36-40	F	18	25	12	52	washing	none	MRI
4	26-30	F	24	34	30	12	checking	skin picking, hypothyroidia	MRI
5	51-55	F	25	40	16	60	washing	none	MRI
6	41-45	M	26	33	32	3	checking, hoarding	social phobia	MRI
7	51-55	F	22	33	2	94	checking	depression, Minkowski-Chauffard syndrome	MRI
8	36-40	F	11	36	6	83	washing	none	MRI
9	26-30	M	10	38	22	42	checking, washing	hypersomnia	CT
10	46-50	F	39	35	25	29	checking	None	CT
11	36-40	F	15	36	30	17	washing	history of eating disorder, history of one seizure, alcoholism, pruritus	MRI
12	36-40	F	5	32	3	91	checking	none	MRI
13	31-35	F	21	30	14	53	checking	dermatillomania	CT

**LONDON (N = 6)**

Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS after “amSTN only” Phase*	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	36-40	F	22	38	32* at 6 mo.	16	washing, repeating	none	MRI
2	36-40	M	22	34	26 at 6 mo.	23	ordering, checking, repeating	body dysmorphic disorder	MRI
3	61-65	M	30	37	17 at 6 mo.	55	washing, checking, repeating	none	MRI
4	36-40	M	20	38	20 at 3 mo.	47	washing, checking, ordering	recurrent depression	MRI
5	51-55	M	23	34	23 at 3 mo.	32	hoarding	recurrent depression	MRI
6	41-45	M	28	36	1 at 3 mo.	97	checking	generalized anxiety disorder, depression	MRI

Notes: \*OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure amSTN” for the first three months or from months four to six postoperatively (and “pure VC/VS” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. AmSTN stimulation was applied via a Medtronic (MDT) model of type 3389, while MDT 3387 leads were implanted for stimulation of the VC/VS target zone (considered only for model validations, see below). Abbreviations: amSTN, anteromedial subthalamic nucleus; CT, computed tomography; F, female; M, male; mo., months; MRI, magnetic resonance imaging; Nr., number; OCD, obsessive-compulsive disorder; postop., postoperative; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

**Table S6.** Summary of demographic and clinical patient characteristics within each retrospective model validation cohort.

Disease cohort	PD	OCD		
<b>Demographic Information</b>				
<b>Cohort</b>	Würzburg	Boston	Cologne	London
<b>Surgical DBS center</b>	University Hospital Würzburg	Massachusetts General Hospital	University Hospital Cologne	National Hospital for Neurology and Neurosurgery
<b>N (female)</b>	32 (10)	7 (4)	22 (13)	6 (1)
<b>Age at time of surgery (mean ± SD; range; in years)</b>	58.00 ± 7.73; 46-79	38.86 ± 16.80; 21-64	42.20 ± 13.38; 21-64	45.50 ± 10.52; 37-62
<b>Disease duration at time of surgery (mean ± SD; range; in years)</b>	10.06 ± 4.21; 3-20	25.14 ± 14.21; 10-44	25.27 ± 12.29; 6-49	24.17 ± 3.92; 20-30
<b>Clinical Outcome</b>				
<b>Surgical target</b>	STN	VC/VS	VC/VS	VC/VS
<b>Main clinical outcome assessment</b>	UPDRS-III <sup>2</sup> (total score; range 0-199, with higher scores corresponding to higher symptom burden)	Y-BOCS <sup>4</sup> (total score; range 0-40, with higher scores corresponding to higher symptom burden)	Y-BOCS <sup>4</sup> (total score; range 0-40, with higher scores corresponding to higher symptom burden)	Y-BOCS <sup>4</sup> (total score; range 0-40, with higher scores corresponding to higher symptom burden)
<b>Time of FU (in months)</b>	mean: 11.5 ± 3.08 SD; range: 6-22	18	12	3 or 6 (post-VC/VS phase) <sup>+</sup>

<b>Comparison basis for calculation of improvement values (baseline to DBS stimulation ON conditions)</b>	Postoperative ON vs. OFF stimulation (ON dopaminergic medication)	Pre- to postoperative	Pre- to postoperative	Pre- to postoperative
<b>Score at baseline (mean ± SD)</b>	45.84 ± 10.93	33.57 ± 2.37	31.12 ± 4.30	36.17 ± 1.83
<b>Score at time of FU under stimulation ON condition (mean ± SD)</b>	24.16 ± 10.65	20.29 ± 10.40	20.70 ± 7.70	17.00 ± 8.74
<b>Rel. improvement (mean ± SD; in %)</b>	46.90 ± 21.11	40.13 ± 29.84	31.00 ± 20.5	52.60 ± 25.51
<b>Abs. improvement (mean ± SD)</b>	21.69 ± 10.96	13.29 ± 9.55	9.60 ± 6.50	19.17 ± 9.39
<b>Imaging and DBS Specifications</b>				
<b>Imaging modality (postop.)</b>	CT (N = 32)	CT (N = 7)	CT (N = 22)	MRI (N = 6)
<b>Electrode models</b>	BSV (N = 23) or BSV Directed (N = 9)	MDT 3387 (N = 7)	MDT 3387 (N = 3) or MDT 3389 (N = 19)	MDT 3387 (N = 6)
<b>Related citations</b>	Butenko et al., 2022 <sup>16</sup>	McLaughlin et al., 2021 <sup>17</sup>	Baldermann et al., 2019 <sup>18</sup> ; Li et al., 2020 <sup>19</sup> ; 2021 <sup>20</sup>	Tyagi et al., 2019 <sup>13</sup>

Notes: \*OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure VC/VS” for the first three months or from months four to six postoperatively (and “pure amSTN” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. VC/VS stimulation was applied via a Medtronic (MDT) model of type 3387 (considered only for model validations), while MDT 3389 leads were implanted for stimulation of the amSTN target zone (considered only for the model set-up step). Abbreviations: Abs., absolute; BSV, Boston Scientific Vercise; CT, computed tomography; DBS, deep brain stimulation; FU, follow-up; MRI, magnetic resonance imaging; OCD, obsessive-compulsive disorder; PD, Parkinson’s disease; postop., postoperative; Rel., relative; SD, standard deviation; UPDRS-III, Unified Parkinson’s Disease Rating Scale – Part III; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

**Table S7:** Patient-wise demographic and clinical characteristics of the Parkinson's disease validation cohorts.

Pat. Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	UPDRS-III Total Preop. Baseline (OFF Medication)	UPDRS-III Total Preop. Baseline (ON Medication)	UPDRS-III Total Postop. (STIM ON at FU)	UPDRS-III Total Percent Improvement ON vs. OFF STIM at FU (%)	LEDD Baseline (OFF DBS)	Time of FU (months)	Postop. Imaging Modality
<b>WÜRZBURG (N = 32)</b>										
1	56-60	M	12	48	9	17	65	81	12	CT
2	56-50	F	9	62	27	38	39	56	12	CT
3	61-65	F	12	42	22	17	60	48	12	CT
4	46-50	M	18	52	34	34	35	35	10	CT
5	56-60	M	7	56	9	17	70	84	16	CT
6	56-60	M	12	49	20	24	51	59	12	CT
7	71-75	M	10	40	20	28	30	50	22	CT
8	56-60	F	11	44	10	8	82	77	12	CT
9	61-65	M	5	45	12	27	40	73	12	CT
10	51-55	F	3	61	34	39	36	44	12	CT
11	61-65	M	11	45	11	32	29	76	12	CT
12	51-55	F	6	31	10	16	48	68	12	CT
13	46-50	M	12	47	20	36	23	57	12	CT
14	46-50	M	7	44	20	14	68	55	13	CT
15	46-50	M	7	38	13	9	76	66	12	CT
16	66-70	M	8	45	5	48	-7	89	13	CT
17	51-55	M	9	50	13	26	48	74	12	CT
18	46-50	M	9	44	17	21	52	61	12	CT
19	61-65	M	6	39	18	35	10	54	12	CT
20	51-55	M	8	16	8	10	38	50	12	CT
21	56-60	M	10	52	38	24	54	27	12	CT
22	56-60	F	18	41	14	22	46	66	12	CT

23	66-70	F	17	45	18	7	84	60	12	CT
24	61-65	M	9	44	23	19	57	48	12	CT
25	76-80	M	5	42	26	25	40	38	12	CT
26	61-65	F	16	39	14	28	28	64	12	CT
27	56-60	M	8	42	33	39	7	21	12	CT
28	46-50	F	12	40	19	20	50	53	6	CT
29	56-60	M	20	85	42	42	51	51	6	CT
30	56-60	M	13	51	25	20	61	51	6	CT
31	51-55	F	6	41	7	14	66	83	6	CT
32	61-65	M	6	47	22	17	64	53	6	CT

Abbreviations: CT, computed tomography; F, female; FU, follow-up; LEDD, levodopa equivalent daily dosage; M, male; MRI, magnetic resonance imaging; Nr., number; postop., postoperative; preop., preoperative; STIM, stimulation; UPDRS-III, Unified Parkinson's Disease Rating Scale – Part III.

**Table S8:** Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder validation cohorts.

**BOSTON (N = 7)**

Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS at 18	Mo. after Surgery	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	56-60	M	41	32	0	100	doubt, checking	n/a	CT	
2	21-25	F	13	35	16	54	doubt, checking	n/a	CT	
3	61-65	F	44	32	21	34	contamination, cleaning	n/a	CT	
4	21-25	M	10	33	29	12	doubt, checking	n/a	CT	
5	26-30	F	11	34	22	35	doubt, checking	n/a	CT	
6	41-45	F	27	31	22	29	contamination, cleaning	n/a	CT	
7	36-40	M	30	38	32	16	contamination, cleaning	n/a	CT	

**COLOGNE (N = 22)**

Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS at 12	Mo. after Surgery	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	36-40	M	24	30	8	73	magical thinking, incompleteness, responsibility	recurrent major depressive disorder (moderate)	CT	
2	31-35	M	15	34	34	0	washing, contamination	none	CT	
3	36-40	M	27	33	24	27	washing, contamination, symmetry, catastrophic fears	none	CT	
4	51-55	M	6	34	12	65	washing, controlling, contamination fears, aggressive thought	none	CT	
5	26-30	M	22	27	14	48	contamination, aggressive impulses, symmetry	none	CT	
6	21-25	M	18	25	20	20	repetition, keeping order, mental exactness, checking	none	CT	
7	21-25	F	15	35	23	34	bodydysmorphobia, checking, magical thinking	hypochondriasis	CT	
8	46-50	M	24	32	22	31	somatic obsessions, contamination fears	none	CT	
9	31-35	M	19	37	34	8	cleanliness, washing, contamination fears, disgust	none	CT	

10	46-50	F	19	28	13	54	checking, aggressive fears, responsibility	none	CT
11	56-60	F	49	36	22	39	aggressive thoughts/impulses, mental urges	recurrent major depressive disorder (severe without psychotic features)	CT
12	26-30	F	6	26	16	38	aggressive impulses, checking, doubting	none	CT
13	61-65	F	20	25	18	28	catastrophic fears, responsibility	anxiety disorder (not otherwise specified); recurrent major depressive disorder (moderate)	CT
14	56-60	M	35	35	25	29	catastrophic fears, responsibility	recurrent major depressive disorder (moderate)	CT
15	26-30	M	18	33	22	33	aggressive impulses, responsibility	recurrent major depressive disorder (severe without psychotic features)	CT
16	56-60	M	44	25	20	20	aggressive impulses, responsibility	recurrent major depressive disorder (severe without psychotic features)	CT
17	36-40	F	29	30	28	7	magical thinking, incompleteness, mental urges	recurrent major depressive disorder (moderate)	CT
18	41-45	F	34	26	21	19	aggressive impulses, responsibility, checking	none	CT
19	41-45	F	39	37	27	27	mental rituals/urges, magical thinking	none	CT
20	51-55	M	42	34	29	15	contamination, cleanliness	none	CT
21	36-40	M	11	36	36	0	responsibility, catastrophic fears, checking	recurrent major depressive disorder (moderate)	CT
22	56-60	F	40	32	11	66	somatic obsessions, sexual obsessions	sedative, hypnotic, or anxiolytic dependence	CT

**LONDON (N = 6)**

Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS after "VC/VS only" Phase*	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	36-40	F	22	38		16	washing, repeating	none	MRI
2	36-40	M	22	34		23	ordering, checking, repeating	body dysmorphic disorder	MRI

3	61-65	M	30	37		55	washing, checking, repeating	none	MRI
4	36-40	M	20	38		47	washing, checking, ordering	recurrent depression	MRI
5	51-55	M	23	34		32	hoarding	recurrent depression	MRI
6	41-45	M	28	36		97	generalized anxiety disorder, checking	depression	MRI

Notes: \*OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure VC/VS” for the first three months or from months four to six postoperatively (and “pure amSTN” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. VC/VS stimulation was applied via a Medtronic (MDT) model of type 3387 (considered only for model validations), while MDT 3389 leads were implanted for stimulation of the amSTN target zone (considered only for the model set-up step). Abbreviations: CT, computed tomography; F, female; M, male; mo., months; MRI, magnetic resonance imaging; Nr., number; OCD, obsessive-compulsive disorder; postop., postoperative; VC/VS, ventral capsule/ventral striatum; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

**Table S9:** Peak voxel coordinates of subthalamic sweet spots and of disease-specific cortical sites of interconnection with sweet tracts.

DYT			TS			PD			OCD				
	(x	y	z)	(x	y	z)	(x	y	z)	(x	y	z)	
<b>Cortical sites of interconnection with sweet tracts (in mm)</b>	Left	(-22.00	-20.00	72.00)	(-3.32	-29.65	-45.59)	(-14.00	2.00	70.00)	(-8.23	-10.29	-16.50)
	Right	(23.50	-18.75	72.00)	(10.00	-12.00	-16.50)	(10.00	2.00	70.00)	(7.88	-9.50	-16.50)
<b>Subthalamic sweet spots (in mm)</b>	Left	(-14.72	-14.38	-4.10)	(-12.96	-11.08	-6.30)	(-12.08	-13.94	-6.74)	(-8.78	-11.52	-9.60)
	Right	(14.54	-13.50	-4.30)	(13.00	-9.98	-6.08)	(11.90	-13.28	-6.74)	(8.38	-10.86	-9.38)

Abbreviations: DYT, dystonia; mm, millimeters; OCD, obsessive-compulsive disorder; PD, Parkinson’s disease; TS, Tourette’s syndrome.

**Table S10:** Overlap between connected streamlines shared among disorders and disease-specific sweet streamlines.

	DYT	PD	TS	OCD
<b>Overlap (%)</b>	4.41	2.21	1.75	5.42
<b>Four-sample test for equality of proportions</b>	p < 2.2e-16			
Pairwise test for equality of proportions				
<b>DYT</b>				
<b>PD</b>	p < 2.2e-16			
<b>TS</b>	p < 2.2e-16	p < 2.84e-14		
<b>OCD</b>	p < 1.35e-11	p < 2.2e-16	p < 2.2e-16	

Abbreviations: DYT, dystonia; mm, millimeters; OCD, obsessive-compulsive disorder; PD, Parkinson's disease; TS, Tourette's syndrome.

**Table S11:** Patient-wise demographic and clinical characteristics of patient cases for prospective model validations.

PD															
Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	PD Phenotype	UPDRS-III Total Postop.		UPDRS-III Total Postop.		UPDRS-III Total Improvement		UPDRS-III Total Improvement		Electrode Model	Clinical Settings	Model-Based Settings	Postop. Imaging Modality
				(STIM OFF, Med.)	(STIM under Clinical Settings, Med.)	(STIM ON under Model-Based Settings, Med.)	(STIM OFF at 3 Mo.)	(ON vs OFF STIM at 3 Mo. postop.)	(ON vs OFF STIM at 3 Mo. postop.)	(under Clinical Settings, Med.)	(under Model-Based Settings, Med.)				
66-70	M	9	Akinetik-rigid	35	14	10	60	71	BSV Directed	Left hemisphere: C+, 1- (60%), 2- (40%) / 2.4 mA / 60 µs / 130 Hz;	Right hemisphere.: C+, 1- (20%), 2- (20%), 3- (3%), 4- (57%) / 2.6 mA / 60 µs / 130 Hz	Left hemisphere: C+, 4- (70%), 7- (30%) / 3 mA / 60 µs / 130 Hz;	Right hemisphere: C+, 7- (30%), 8- (70%) / 3 mA / 60 µs / 130 Hz	CT	
<i>PD patient implanted to the STN at Würzburg University Hospital (Würzburg, Germany)</i>															

## OCD

Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	OCD Phenotype	Comorbidities	Previous treatments	Y-BOCS Total Preop.	Y-BOCS Total								Model-Based Settings	Postop. Imaging Modality			
							Postop. (STIM)		Y-BOCS Total		Y-BOCS Total		Improvement						
							ON under Clinical	ON under Model-Based	Preop. vs. STIM	ON at 1 Mo.	STIM ON at 1 Mo. Postop.	Electrode Model	Clinical Settings						

## OCD patient implanted to the VC/VS region at Massachusetts General Hospital (Boston, USA)

21-25	F	13	obsessions about food and water intake, compulsions involving ingestion events; skin picking	major depressive disorder	11 different medication trials (including multiple SSRIs, clomipramine, and ketamine), intensive ERP, ECT	35	29	22	17	37	MDT 3387	Right hemisphere: C+, 9- / 2.4 mA / 140 µs / 130 Hz;	Left hemisphere: C+, 1- , 2- / 3 mA / 140 µs / 130 Hz;	Left hemisphere: C+, 2- / 4.2 mA / 80 µs / 130 Hz;	Right hemisphere: C+, 10- / 3.4 mA / 80 µs / 130 Hz;	CT
-------	---	----	--	---------------------------	---	----	----	----	----	----	----------	--	--	--	--	----

## OCD patient implanted to the STN at Clínica de Dor e Funcional (São Paulo, Brazil)

31-35	M	14	compulsion of noting words unknown to the patient and transcribing their meaning from dictionaries; death-related intrusions leading to compulsive religious rituals	apathy, major depressive disorder	48 sessions of ECT, CBT, biofeedback, mindfulness training, 3 different protocols of TMS with over 50 sessions	26	-	6	-	77	BSV	-	Left hemisphere: C+, 1- (100%) / 3 V / 90 µs / 130 Hz;	Right hemisphere: C+, 9- (100%) / 3 V / 90 µs / 130 Hz;	CT
-------	---	----	--	-----------------------------------	--	----	---	---	---	----	-----	---	--	---	----

Abbreviations: BSV, Boston Scientific Vercise; CBT, cognitive behavioral therapy; CT, computed tomography; ECT, electroconvulsive therapy; ERP, exposure and response prevention therapy; F, female; Hz, Hertz; M, male; mA, milliamperere; Mo., months; MDT, Medtronic; postop., postoperative; preop., preoperative; postop., postoperative; SSRI, selective serotonin inhibitor; STIM, stimulation; STN, subthalamic nucleus; TMS, transcranial magnetic stimulation; UPDRS III, Unified Parkinson's Disease Rating Scale – Part III; VC/VS, ventral capsule/ventral striatum; V, volt; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

## References

1. Burke, R. E. *et al.* Validity and reliability of a rating scale for the primary torsion dystonias. *Neurology* **35**, 73–77 (1985).
2. Goetz, C. G. *et al.* Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan. *Mov. Disord.* **22**, 41–47 (2007).
3. Leckman, J. F. *et al.* The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. *J. Am. Acad. Child Adolesc. Psychiatry* **28**, 566–573 (1989).
4. Goodman, W. K. *et al.* The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. *Arch. Gen. Psychiatry* **46**, 1006–1011 (1989).
5. Ostrem, J. L. *et al.* Subthalamic nucleus deep brain stimulation in primary cervical dystonia. *Neurology* **76**, 870–878 (2011).
6. Ostrem, J. L. *et al.* Subthalamic nucleus deep brain stimulation in isolated dystonia: A 3-year follow-up study. *Neurology* **88**, 25–35 (2016).
7. Lin, S. *et al.* Deep brain stimulation of the globus pallidus internus versus the subthalamic nucleus in isolated dystonia. *J. Neurosurg.* **132**, 721–732 (2019).
8. He, W. *et al.* Weight change after subthalamic nucleus deep brain stimulation in patients with isolated dystonia. *Front. Neurol.* **12**, 1–8 (2021).
9. Horn, A. *et al.* Connectivity predicts deep brain stimulation outcome in Parkinson's disease. *Ann. Neurol.* **82**, 67–78 (2017).
10. Horn, A. *et al.* Deep brain stimulation induced normalization of the human functional connectome in Parkinson's disease. *Brain* **142**, 3129–3143 (2019).
11. Vissani, M. *et al.* Spatio-temporal structure of single neuron subthalamic activity identifies DBS target for anesthetized Tourette Syndrome patients. *J. Neural Eng.* **16**, 066011 (2019).
12. Dai, L. *et al.* Subthalamic deep brain stimulation for refractory Gilles de la Tourette's syndrome: Clinical outcome and functional connectivity. *J. Neurol.* **269**, 6116–6126 (2022).
13. Tyagi, H. *et al.* A randomized trial directly comparing ventral capsule and anteromedial subthalamic nucleus stimulation in obsessive-compulsive disorder: Clinical and imaging evidence for dissociable effects. *Biol. Psychiatry* **85**, 726–734 (2019).
14. Polosan, M. *et al.* Affective modulation of the associative-limbic subthalamic nucleus: deep brain stimulation in obsessive-compulsive disorder. *Transl. Psychiatry* **9**, (2019).
15. Schiess, M. C., Zheng, H., Soukup, V. M., Bonnen, J. G. & Nauta, H. J. W. Parkinson's disease subtypes: Clinical classification and ventricular cerebrospinal fluid analysis. *Park. Relat. Disord.* **6**, 69–76 (2000).
16. Butenko, K. *et al.* Linking profiles of pathway activation with clinical motor improvements – A retrospective computational study. *NeuroImage Clin.* **36**,

103185 (2022).

17. McLaughlin, N. C. R. *et al.* Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design. *Contemp. Clin. Trials Commun.* **22**, 100785 (2021).
18. Baldermann, J. C. *et al.* Connectivity profile predictive of effective deep brain stimulation in obsessive-compulsive disorder. *Biol. Psychiatry* **85**, 735–743 (2019).
19. Li, N. *et al.* A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder. *Nat. Commun.* **11**, 3364 (2020).
20. Li, N. *et al.* A unified functional network target for deep brain stimulation in obsessive-compulsive disorder. *Biol. Psychiatry* **90**, 701–713 (2021).